Ligand Pharmaceuticals (LGND) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.74% |
| Dec 31, 2025 | 7.42% |
| Sep 30, 2025 | 13.76% |
| Jun 30, 2025 | 6.32% |
| Mar 31, 2025 | 6.75% |
| Dec 31, 2024 | 3.61% |
| Sep 30, 2024 | 19.23% |
| Jun 30, 2024 | 10.97% |
| Mar 31, 2024 | 6.52% |
| Dec 31, 2023 | -0.98% |
| Sep 30, 2023 | 4.71% |
| Jun 30, 2023 | 8.41% |
| Mar 31, 2023 | 5.42% |
| Dec 31, 2022 | 26.50% |
| Sep 30, 2022 | 19.14% |
| Jun 30, 2022 | 15.49% |
| Mar 31, 2022 | 8.39% |
| Dec 31, 2021 | 14.87% |
| Sep 30, 2021 | 14.65% |
| Jun 30, 2021 | 17.06% |
| Mar 31, 2021 | 15.34% |
| Dec 31, 2020 | 27.62% |
| Sep 30, 2020 | 22.24% |
| Jun 30, 2020 | 14.37% |
| Mar 31, 2020 | 14.17% |
| Dec 31, 2019 | 20.55% |
| Sep 30, 2019 | 11.21% |
| Jun 30, 2019 | 16.78% |
| Mar 31, 2019 | 20.94% |
| Dec 31, 2018 | 31.69% |
| Sep 30, 2018 | 28.97% |
| Jun 30, 2018 | 26.39% |
| Mar 31, 2018 | 32.30% |
| Dec 31, 2017 | 56.74% |
| Sep 30, 2017 | 38.96% |
| Jun 30, 2017 | 27.10% |
| Mar 31, 2017 | 53.51% |
| Dec 31, 2016 | 49.15% |
| Sep 30, 2016 | 38.97% |
| Jun 30, 2016 | 30.65% |
| Mar 31, 2016 | 55.56% |
| Dec 31, 2015 | 56.79% |
| Sep 30, 2015 | 38.47% |